MNG278
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.482
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.469
- IL6_JAK_STAT3_SIGNALING+0.440
- TNFA_SIGNALING_VIA_NFKB+0.396
- HYPOXIA+0.389
- APOPTOSIS+0.361
- P53_PATHWAY+0.350
- INFLAMMATORY_RESPONSE+0.347
- COMPLEMENT+0.339
- IL2_STAT5_SIGNALING+0.339
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.349
- MYC_TARGETS_V1-0.293
- SPERMATOGENESIS-0.132
- UNFOLDED_PROTEIN_RESPONSE-0.109
- UV_RESPONSE_DN-0.064
- ANDROGEN_RESPONSE-0.019
- PEROXISOME-0.010
- HEDGEHOG_SIGNALING-0.007
- PROTEIN_SECRETION+0.000
- INTERFERON_ALPHA_RESPONSE+0.027
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KXMYBQ6N | Spinal Cord Ependymoma | — | 0.861 |
| 2 | A3874F0D-53A9-43C8-87EE-65C12C0F8135 | — | — | 0.830 |
| 3 | BS_QWTE1CWR | high-grade glioma | — | 0.826 |
| 4 | BS_VMQMGSJY | high-grade glioma | — | 0.824 |
| 5 | 6727027F-4BAB-41ED-87F3-ECC7B1718ECF | — | — | 0.824 |
| 6 | EPT1044 | EPN | Posterior Fossa EPN | 0.823 |
| 7 | 47E7CB22-BC33-4D50-AF1B-5134C350B9D4 | — | — | 0.821 |
| 8 | 718de66e-06d2-4c2c-8b2d-e40087c4340c | — | — | 0.815 |
| 9 | D2201D51-9020-4A0D-B2C8-8F7A2F0A918A | — | — | 0.812 |
| 10 | BS_M85CXHDV | high-grade glioma | — | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.482 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.469 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.396 | Inavolisib | — uncovered |
| HYPOXIA | 0.389 | Idelalisib | — uncovered |
| APOPTOSIS | 0.361 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.350 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.347 | Idelalisib | — uncovered |
| COMPLEMENT | 0.339 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.339 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.323 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.321 | Idelalisib | — uncovered |
| COAGULATION | 0.318 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.307 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.301 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.257 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.241 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |